Characteristics	Number	%
Age(year)	47.94±13.250
Range 1 2-85
Median	48. 00
Male: Female	13 5:48
Histology
WHOType I	20	10.9
WHOType II	41	22.4
WHOType III	122	6.7
Stage(AJCC2010)
StageI	15	8.2
StageII	45	24.6
StageIII	96	52.5
StageIV	27	14.8
T Classification
T1	35	19.1
T2	73	39.9
T3	56	30.6
T4	19	10.4
N Classification
N0	43	23.5
N1	83	45.4
N2	48	26.2
N3	9	4.9
M Classification
M0	178	97.3
M1	5	2.7
Primary Treatment
RT	20	11. 0
NAC+RT+CCRT	14	24. 0
CCRT+RT+AC	119	65. 0

Table 1:AJCC, America Joint Committee on Cancer; RT, Radiotherapy, NAC, Neo-adjuvant Chemotherapy, CCRT, Concurrent Chemotherapy

Univariate analysis of prognostic factors for OS and PFS
Factors	n()	5-year OS rate(%)	x2	*P value	5year PFS rate(%)	x2	*P value
Age-group	103	58.3	5.208	0.022	53.4	4.773	0.029
<50	80	41.3			32.5
50 and above
Gender
Male	135	43.8	4.15	0.042	39.6	4.38	0.036
Female	48	60.3			59.3
Stage (AJCC 2014)
Stage I	15	66.7	9.275	0.026	60. 0	8.103	0.044
Stage I I	45	55.6			51.1
Stage I I I	96	41.8			36.6
Stage IV	27	25.9			18.6
T classification
T1	35	57.1	9.119	0.028	51.4	9.737	0.021
T2	73	54.4			50.7
T3	56	41.4			35.7
T4	19	21.3			15.8
M classification
M0	178	50.6	4.975	0.026	48.3	4.558	0.035
M1	5	0. 00			0. 00

Primary treatment
RT	20	42.1	8.921	0.012	36.8	10.5	0.005
NAC+RT+CCRT	44	50.4			45.5
CCRT+RT+AC	119	69.7			67.2
Treatment	Effects
NC	11	9.1	16.567	0.001	0 .0	20.061	0. 000
PD	14	14.4			7.1
PR	34	47.1			41.2
CR	124	56.5			52.4

Table 2: AJCC, America Joint Committee on Cancer; RT, Radiotherapy, NAC, Neo-adjuvant Chemotherapy; AC, Adjuvant Chemotherapy, CCRT, Concurrent Chemotherapy; CR, complete response; PR , partial response; NC, no change; PD, progression disease; OS, overall survival; PFS, progression free survival

Variable	Patients	Hazard ratio	95% CI	*P value	Hazard ratio	95% CI	*P value
Age group <50	103	1.12	1.41- 3.82	0.043	2.052	1.20-3.05	0.017
50 and above	80
Gender
Male	135	0.35	0.147-0.817	0.01	0.383	0.189-0.776	0.07
Female	48
Histology
WHO Type I	20	2.57	0.841-1.853	0.088	1.408	0.667-2.969	0.368
WHO Type II	41
WHO Type III	122
Stage (AJCC 2010)
Stage I	15	0.748	0.317-1.764	0.034	1.008	0.502-2.025	0.029
Stage II	45
Stage III	96
Stage IV	27
T classification
T1	35	1.427	0.610-3.337	0.025	1.05	0.54-2.039	0. 000
T2	73
T3	56
T4	19
N classification
N0	43	0.904	0.464-1.758	0.765	1.232	0.622-2.437	0.547
N1	83
N2	48
N2	9
M classification
M0	178	4.278	0.679-26.940	0.019	4.304	0.697-26.576	0.046
M1
Primary treatment
RT	20	2.114	1.123 -3.978	0. 000	0.636	0.322-1.254	0.01 0
NAC+RT+CCRT	44
CCRT+RT+CCRT	119
Treatment Effects
NC	14	1.165	0.611-2.224	0.004	1.364	0.696- 2.674	0.03 0
PD	17
PR	34
CR	118

AJCC, America Joint Committee on Cancer; RT, Radiotherapy, NAC, Neo-adjuvant Chemotherapy, CCRT, Concurrent Chemotherapy; CR, complete response; PR , partial response; NC, no change; PD, progression disease; OS, overall survival; PFS, progression free-survival; CI, confidence interval.

Factors	N=183	RT(n=20)	NAC+RT+CCRT(n=44)	CCRT+RT+AC(n=119)	x2	*P value
Age group
Less than 50	103	13	20	65	1.961	0.375
50 and above	80	7	23	54
Gender
Male	135	10	34	91	1.201	0.319
Female	48	7	10	31
Histology
WHO Type I	20	1	5	14	3.374	0.497
WHO Type II	41	7	7	27
WHO Type III	122	12	32	78
Stage(AJCC2010)
Stage I	15	15	2	28	70.487	0. 000
Stage II	45	3	24	30
Stage III	96	1	2	47
Stage IV	27	1	16	14
T classification
T1	35	15	2	28	49.873	0. 000
T2	73	3	17	37
T3	56	1	9	40
T4	19	1	16	14
M classification
M0	178	20	44	119	8.434	0 .004
M1	5		1	4

Table 4: Characteristics of patients’ different primary treatment modalities

			OS rate (%)						PFS rate (%)
Variable No. of	RT	NAC+RT+CCRT	CCRT+RT+AC	RT		NAC+RT+ CCRT					C CRT+RT+AC
Patients=183		(n=20)	(n=44)	(n=119)	x2	*P value	(n=20)	(n=44)	(n=119)	x2	*P value
Stage(AJCC2010)
Stage I	60	34	58.3	62.7	62.451	0. 00	26.9	43.9	56	61.202	0. 000
Stage II	96	28.6	44.3	58.7			15. 0	36.1	50.2
Stage III	27	0. 0	20. 0	36. 7			0. 0	10. 5	23. 6
T classification
T1	35	28.9	47.54	60 .0	0. 028	0.06 0	25.36	44.32	54.4	0.025	0.067
T2	73	20.9	34.6	47.3			19.6	26	45.7
T3	59	17.1	26.1	45. 0			15.3	17.2	33.6
T4	19	5.26	22.9	44. 4			4.9	12.3	30
N classification
N0	43	39.2	44.4	52.1	0.165	0.059	30.2	38.3	47.8	0.122	0.07 0
N1	83	30.2	38.6	46.9			28.3	23.3	46.5
N2	48	14.5	29.5	44.1			10.4	21.6	22.7
N3	9	8.3	11.1	12.6			1.2	2. 0	7. 6
M classification
M0	178	29.21	54.8	60.6	0.629	0.73	11.7	32.02	46.4	4.957	0.175
M1	5	0	8. 87	10.2			0. 0	1.53	5. 70

Table 5: Five year OS and PFS rates of different stages and treatment modalities